LncRNA BBOX1‐AS1 targets miR‐361‐3p/COL1A1 axis to drive the progression of oesophageal carcinoma

Abstract

Oesophageal cancer (EC), the eighth of the most prevalent cancer in the world, is one of the fatal malignancies. 1 Despite many improvements in the management and therapy of oesophageal cancer patients, the outcomes remained really poor. 2 As the lack of early clinical symptoms, oesophageal cancer is often diagnosed during its advance stages. 3 Hence, there is a need for figuring out novel susceptible genes and potent biomarkers for diagnosis and

A review on the role of gamma-butyrobetaine hydroxylase 1 antisense RNA 1 in the carcinogenesis and tumor progression

“…In respiratory system tumors, BBOX1-AS1 exhibits a significant positive correlation with larger tumor size, lymph node metastasis, and advanced Tumour-Node-Metastasis (TNM) stage in NSCLC [ 39 , 40 ]. Similarly, in digestive system tumors [ 41 , 43 , 44 , 46 – 48 ], BBOX1-AS1 shows a significant positive association with larger tumor size, lymph node metastasis, or advanced TNM stage. Notably, high BBOX1-AS1 expression is positively correlated with lymph node metastasis in esophageal carcinoma [ 41 , 44 ] and gastric cancer [ 48 ].…”

“…Similarly, in digestive system tumors [ 41 , 43 , 44 , 46 – 48 ], BBOX1-AS1 shows a significant positive association with larger tumor size, lymph node metastasis, or advanced TNM stage. Notably, high BBOX1-AS1 expression is positively correlated with lymph node metastasis in esophageal carcinoma [ 41 , 44 ] and gastric cancer [ 48 ]. Elevated BBOX1-AS1 expression is linked to positive vascular invasion, higher tumor grade, and advanced clinical stage in hepatocellular carcinoma [ 46 , 47 ].…”

“…Several studies have reported a significant relationship between aberrant BBOX1-AS1 expression and cancer patient prognosis. As indicated in Table 1 , high expression of BBOX1-AS1 was found to predict poor overall survival in four types of cancers: non-small cell lung cancer [ 39 , 40 ], esophageal squamous cell carcinoma [ 41 , 43 , 44 ], hepatocellular carcinoma [ 46 , 47 ], and cervical cancer [ 53 ], as well as inferior disease-free survival in hepatocellular carcinoma [ 47 ]. Additionally, several prognostic models that incorporate BBOX1-AS1 have been developed.…”

“…For instance, in NPC, two different ceRNA mechanisms involving BBOX1-AS1 have been identified: BBOX1-AS1 can promote the proliferation, migration, and invasion of NPC cells by targeting miR-3940-3p/KPNA2 axis [ 37 ] and miR-204-5p/MUC4 axis [ 36 ]. Similarly, in esophageal carcinoma [ 41 , 42 , 44 , 45 ], BBOX1-AS1 interacts with three miRNAs (miR-506-5p, miR-513a-3p, miR-361-3p) and subsequently upregulates the expression of four target genes (EIF5A, SLC7A11, COL5A1, COL1A1), promoting tumor cell growth, migration, invasion, and accelerating the progression and metastasis of esophageal cancer.…”

“…BBOX1-AS1 demonstrates upregulation in a wide range of human tumors (Fig. 1 ), including pituitary adenoma (PA) [ 34 ], oral squamous cell carcinoma (OSCC) [ 35 ], nasopharyngeal carcinoma (NPC) [ 36 , 37 ], non-small cell lung cancer (NSCLC) [ 38 – 40 ], esophageal carcinoma (EC) [ 41 – 45 ], hepatocellular carcinoma (HCC) [ 46 , 47 ], gastric cancer (GC) [ 48 ], colorectal cancer (CRC) [ 49 , 50 ], ovarian cancer (OC) [ 51 ], and cervical cancer (CC) [ 52 , 53 ]. High expression levels of BBOX1-AS1 in tumor patients have been linked to adverse clinicopathological features and poor prognosis, including lymph node metastasis, tumor size, clinical stage, overall survival (OS), and disease-free survival (DFS).…”